Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02362997 · OUTCOME

Response Rate to Pembrolizumab

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL · Source last updated 2026-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
proportion of participants
Interval / dispersion
90% Confidence Interval
Time frame
18 months

What was measured

In patients with measurable disease after ASCT, rate of objective response after treatment. Response was assessed using the Lugano 2014 criteria.

Groups in this outcome

Diffuse Large B Cell Lymphoma

Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody

Classical Hodgkin Lymphoma

Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody

Peripheral T Cell Lymphoma

Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Diffuse Large B Cell Lymphoma31
Classical Hodgkin Lymphoma30
Peripheral T Cell Lymphoma21

Reported measurements

Source class 1
Values in proportion of participants · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Diffuse Large B Cell Lymphoma0.74Not reported0.580.86Not reported
Classical Hodgkin Lymphoma0.90Not reported0.760.97Not reported
Peripheral T Cell Lymphoma0.86Not reported0.670.96Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.58
        upper Limit
        0.86
        value
        0.74
      2. group Id
        OG001
        lower Limit
        0.76
        upper Limit
        0.97
        value
        0.90
      3. group Id
        OG002
        lower Limit
        0.67
        upper Limit
        0.96
        value
        0.86
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    2. group Id
      OG001
      value
      30
    3. group Id
      OG002
      value
      21
    units
    Participants
description
In patients with measurable disease after ASCT, rate of objective response after treatment. Response was assessed using the Lugano 2014 criteria.
dispersion Type
90% Confidence Interval
groups
  1. description
    Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody
    id
    OG000
    title
    Diffuse Large B Cell Lymphoma
  2. description
    Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody
    id
    OG001
    title
    Classical Hodgkin Lymphoma
  3. description
    Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody
    id
    OG002
    title
    Peripheral T Cell Lymphoma
param Type
NUMBER
reporting Status
POSTED
time Frame
18 months
title
Response Rate to Pembrolizumab
type
SECONDARY
unit Of Measure
proportion of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice